ClinicalTrials.gg
CompletedNCT01897233Updated Jun 20, 2017Results posted

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

A Phase 3 interventional study of Lumacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 20 sites in 2 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
11th of 20
62 · median 66
Started
2013
with 6 others
Phase 3
10 of 20
none open now
Registered
8th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 11th largest by enrollment, is one of 7 that started in 2013, is one of 10 in phase 3, and was the 8th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF defined as: with 2 CF-causing mutations, chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities
  • Subjects who weigh ≥15 kg without shoes at Screening Visit
  • Subjects who are homozygous for the F508del-CFTR mutation
  • Subjects with percent predicted (FEV1) of 70% to 105% (inclusive) (Part A) or ≥40% (Part B) at Screening Visit where the predicted values are adjusted for age, sex, and height using the Wang equation
  • Subjects with stable CF disease and who are willing to remain on stable CF medication regimen
  • Able to swallow tablets

Exclusion criteria

Exclusion Criteria:

  • History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject
  • Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1 of the study
  • Abnormal liver function as defined in the protocol at Screening Visit
  • Abnormal renal function as defined in the protocol at Screening Visit
  • History of solid organ or hematological transplantation
  • Ongoing participation in an drug study or prior participation in an investigational drug study within 30 days prior of Screening Visit
  • History or evidence of lens opacity or cataract at Screening Visit
  • Colonization with organisms associated with a more rapid decline in pulmonary status at Screening Visit (Part A only)
  • A standard 12-lead demonstrating >450 msec at Screening Visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Lumacaftor/Ivacaftor (LUM/IVA)

    Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days. Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days. Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks.

    Drug: Lumacaftor · Drug: Ivacaftor

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 1

    Time frame: 4 hours post-morning dose on Day 1

  2. Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 14

    Time frame: 4 hours post-morning dose on Day 14

  3. Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to End of Dosing Interval (AUCtau) of Lumacaftor (LUM) and Ivacaftor (IVA)

    The AUCtau is the area under the concentration versus time curve from time 0 to time tau, where tau is the time at the end of dosing interval.

    Time frame: Day 14 (pre-morning dose, 4, 6, 12, and 24 hours post-morning dose for LUM; pre-morning dose, 2, 4, 6, 12 hours post-morning dose for IVA)

  4. Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose to Week 26 were considered treatment-emergent.

    Time frame: Day 1 up to Week 26

Secondary outcomes

  1. Part A: Observed Plasma Concentration of Lumacaftor Metabolite (M28-LUM) and Ivacaftor Metabolites (M1-IVA and M6-IVA) at Hour 4 Post-dose (C4h) on Day 1 and 14

    Time frame: Day 1, Day 14

  2. Part A: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose through the end of Part A were considered treatment-emergent.

    Time frame: Day 1 up to Day 28

  3. Part B: Average Absolute Change From Baseline in Sweat Chloride at Day 15 and at Week 4

    Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Average of Day 15 and Week 4 measurements was taken and change was calculated as: Average (Day 15 and Week 4 measurement) minus Baseline measurement.

    Time frame: Baseline, Day 15 and Week 4

  4. Part B: Absolute Change in Sweat Chloride From Week 24 at Week 26

    Sweat samples were collected using an approved collection device. Change = Week 26 minus Week 24.

    Time frame: Week 24, Week 26

  5. Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

    BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

    Time frame: Baseline, Week 24

  6. Part B: Absolute Change From Baseline in BMI-for-age Z-score at Week 24

    BMI was defined as weight in kg divided by height\*height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.

    Time frame: Baseline, Week 24

  7. Part B: Absolute Change From Baseline in Weight at Week 24

    Time frame: Baseline, Week 24

  8. Part B: Absolute Change From Baseline in Weight-for-age Z-score at Week 24

    Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.

    Time frame: Baseline, Week 24

  9. Part B: Absolute Change From Baseline in Height at Week 24

    Time frame: Baseline, Week 24

  10. Part B: Absolute Change From Baseline in Height-for-age Z-score at Week 24

    Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.

    Time frame: Baseline, Week 24

  11. Part B: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24

    The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Week 24

  12. Part B: Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains at Week 24

    The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.

    Time frame: Baseline, Week 24

  13. Part B: Pre-dose Concentration (Ctrough) and 3 to 6 Hours Post-dose Concentration (C3-6hr) of Lumacaftor, Lumacaftor Metabolite (M28-LUM), Ivacaftor and Ivacaftor Metabolites (M1-IVA and M6-IVA)

    Ctrough and C3-6hr for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. Ctrough was observed pre-dose concentration. C3-6hr was observed concentration at 3 to 6 hours post- dose.

    Time frame: For Ctrough: pre-morning dose on Week 4, Week 6 and Week 24; For C3-6hr: 3 to 6 hours post-morning dose on Day 1, 15 and Week 4

07

Results

Posted Dec 5, 2016
Limitations and caveats
Due to limited sampling and instances of missing data, C4h was reported instead of Cmax as an approximation of maximum concentration. Sparse PK sampling scheme was optimized around parent compounds which limited the estimation of AUC for metabolites.

Participant flow

Part A (14 Days)
Participant flow — Part A (14 Days)
MilestoneLumacaftor/Ivacaftor (LUM/IVA)
Started10
Part a cohort 1 (6 to 8 years)5
Part a cohort 2 (9 to 11 years)5
Completed10
Not completed0
Part B (24 Weeks)
Participant flow — Part B (24 Weeks)
MilestoneLumacaftor/Ivacaftor (LUM/IVA)
Started58
Completed54
Not completed4
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Physician decision1

Outcome measures

PrimaryPart A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 1
Time frame:
4 hours post-morning dose on Day 1
Reported as:
Mean · nanogram per milliliter (ng/mL)
Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 1
nanogram per milliliter (ng/mL)Part A Overall Arm: LUM/IVA
LUM15200 ± 6740
IVA1920 ± 727
PrimaryPart A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 14
Time frame:
4 hours post-morning dose on Day 14
Reported as:
Mean · ng/mL
Part A: Observed Plasma Concentration of Lumacaftor (LUM) and Ivacaftor (IVA) at Hour 4 Post-dose (C4h) on Day 14
ng/mLPart A Overall Arm: LUM/IVA
LUM24500 ± 10400
IVA622 ± 322
PrimaryPart A: Area Under the Plasma Concentration-Time Curve From Time 0 to End of Dosing Interval (AUCtau) of Lumacaftor (LUM) and Ivacaftor (IVA)

The AUCtau is the area under the concentration versus time curve from time 0 to time tau, where tau is the time at the end of dosing interval.

Time frame:
Day 14 (pre-morning dose, 4, 6, 12, and 24 hours post-morning dose for LUM; pre-morning dose, 2, 4, 6, 12 hours post-morning dose for IVA)
Reported as:
Median · ng*hr/mL
Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to End of Dosing Interval (AUCtau) of Lumacaftor (LUM) and Ivacaftor (IVA)
ng*hr/mLPart A Overall Arm: LUM/IVA
LUM387600 (280700 to 640800)
IVA6838 (2689 to 12100)
PrimaryPart B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose to Week 26 were considered treatment-emergent.

Time frame:
Day 1 up to Week 26
Reported as:
Number · participants
Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPart B: LUM/IVA
AEs55
SAEs4
SecondaryPart A: Observed Plasma Concentration of Lumacaftor Metabolite (M28-LUM) and Ivacaftor Metabolites (M1-IVA and M6-IVA) at Hour 4 Post-dose (C4h) on Day 1 and 14
Time frame:
Day 1, Day 14
Reported as:
Mean · ng/mL
Part A: Observed Plasma Concentration of Lumacaftor Metabolite (M28-LUM) and Ivacaftor Metabolites (M1-IVA and M6-IVA) at Hour 4 Post-dose (C4h) on Day 1 and 14
ng/mLPart A Overall Arm: LUM/IVA
M28-LUM (Day 1)176 ± 79.0
M1-IVA (Day 1)3940 ± 1380
M6-IVA (Day 1)1810 ± 981
M28-LUM (Day 14)2040 ± 1230
M1-IVA (Day 14)2380 ± 1360
M6-IVA (Day 14)4240 ± 1990
SecondaryPart A: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first study drug dose through the end of Part A were considered treatment-emergent.

Time frame:
Day 1 up to Day 28
Reported as:
Number · participants
Part A: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPart A Overall Arm: LUM/IVA
Part A Cohort 1: AEs (n=5)4
Part A Cohort 1: SAEs (n=5)0
Part A Cohort 2: AEs (n=5)3
Part A Cohort 2: SAEs (n=5)0
SecondaryPart B: Average Absolute Change From Baseline in Sweat Chloride at Day 15 and at Week 4

Sweat samples were collected using an approved collection device. Baseline was defined as the average of the measurements at screening and on Day 1 pre-dose. Average of Day 15 and Week 4 measurements was taken and change was calculated as: Average (Day 15 and Week 4 measurement) minus Baseline measurement.

Time frame:
Baseline, Day 15 and Week 4
Reported as:
Least squares mean · millimole per liter (mmol/L)
Part B: Average Absolute Change From Baseline in Sweat Chloride at Day 15 and at Week 4
millimole per liter (mmol/L)Part B: LUM/IVA
Part B: Average Absolute Change From Baseline in Sweat Chloride at Day 15 and at Week 4-19.7 (-23.2 to -16.3)
SecondaryPart B: Absolute Change in Sweat Chloride From Week 24 at Week 26

Sweat samples were collected using an approved collection device. Change = Week 26 minus Week 24.

Time frame:
Week 24, Week 26
Reported as:
Least squares mean · mmol/L
Part B: Absolute Change in Sweat Chloride From Week 24 at Week 26
mmol/LPart B: LUM/IVA
Part B: Absolute Change in Sweat Chloride From Week 24 at Week 2621.3 (18.6 to 24.0)
SecondaryPart B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI was defined as weight in kilogram (kg) divided by height\*height in square meter (m\^2).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilogram per square meter (kg/m^2)
Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
kilogram per square meter (kg/m^2)Part B: LUM/IVA
Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 240.64 (0.46 to 0.83)
SecondaryPart B: Absolute Change From Baseline in BMI-for-age Z-score at Week 24

BMI was defined as weight in kg divided by height\*height in m\^2. z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score). The BMI-for-age z-scores were calculated using National Center for Health Statistics growth charts.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change From Baseline in BMI-for-age Z-score at Week 24
z-scorePart B: LUM/IVA
Part B: Absolute Change From Baseline in BMI-for-age Z-score at Week 240.15 (0.08 to 0.22)
SecondaryPart B: Absolute Change From Baseline in Weight at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilograms (kg)
Part B: Absolute Change From Baseline in Weight at Week 24
kilograms (kg)Part B: LUM/IVA
Part B: Absolute Change From Baseline in Weight at Week 242.6 (2.2 to 3.0)
SecondaryPart B: Absolute Change From Baseline in Weight-for-age Z-score at Week 24

Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (weight z-score). The weight-for-age z-scores were calculated using National Center for Health Statistics growth charts.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change From Baseline in Weight-for-age Z-score at Week 24
z-scorePart B: LUM/IVA
Part B: Absolute Change From Baseline in Weight-for-age Z-score at Week 240.13 (0.07 to 0.19)
SecondaryPart B: Absolute Change From Baseline in Height at Week 24
Time frame:
Baseline, Week 24
Reported as:
Least squares mean · centimeter (cm)
Part B: Absolute Change From Baseline in Height at Week 24
centimeter (cm)Part B: LUM/IVA
Part B: Absolute Change From Baseline in Height at Week 242.9 (2.6 to 3.2)
SecondaryPart B: Absolute Change From Baseline in Height-for-age Z-score at Week 24

Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from -infinity to +infinity; where 0: same mean, \>0: a greater mean, and \<0: a lesser mean than the standard. Height, adjusted for age and sex, was analyzed as height-for-age z-score (height z-score). The height-for-age z-scores were calculated using National Center for Health Statistics growth charts.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · z-score
Part B: Absolute Change From Baseline in Height-for-age Z-score at Week 24
z-scorePart B: LUM/IVA
Part B: Absolute Change From Baseline in Height-for-age Z-score at Week 240.03 (-0.02 to 0.09)
SecondaryPart B: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24

The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a scale
Part B: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24
Units on a scalePart B: LUM/IVA
Part B: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 245.4 (1.4 to 9.4)
SecondaryPart B: Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains at Week 24

The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Part B: Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domains at Week 24
units on a scalePart B: LUM/IVA
Change at Week 24: Effectiveness9.2 (4.3 to 14.1)
Change at Week 24: Side Effects-0.3 (-1.4 to 0.8)
Change at Week 24: Convenience11.1 (7.1 to 15.1)
Change at Week 24: Global Score3.6 (-2.0 to 9.1)
SecondaryPart B: Pre-dose Concentration (Ctrough) and 3 to 6 Hours Post-dose Concentration (C3-6hr) of Lumacaftor, Lumacaftor Metabolite (M28-LUM), Ivacaftor and Ivacaftor Metabolites (M1-IVA and M6-IVA)

Ctrough and C3-6hr for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. Ctrough was observed pre-dose concentration. C3-6hr was observed concentration at 3 to 6 hours post- dose.

Time frame:
For Ctrough: pre-morning dose on Week 4, Week 6 and Week 24; For C3-6hr: 3 to 6 hours post-morning dose on Day 1, 15 and Week 4
Reported as:
Mean · ng/mL
Part B: Pre-dose Concentration (Ctrough) and 3 to 6 Hours Post-dose Concentration (C3-6hr) of Lumacaftor, Lumacaftor Metabolite (M28-LUM), Ivacaftor and Ivacaftor Metabolites (M1-IVA and M6-IVA)
ng/mLPart B: LUM/IVA
C3-6h LUM (Day 1) (n=57)17100 ± 6260
C3-6h IVA (Day 1) (n=57)1980 ± 850
C3-6h M28-LUM (Day 1) (n=57)186 ± 96.3
C3-6h M1-IVA (Day 1) (n=57)4170 ± 1940
C3-6h M6-IVA (Day 1) (n=57)2040 ± 1650
C3-6h LUM (Day 15) (n=55)21400 ± 6850
C3-6h IVA (Day 15) (n=55)751 ± 433
C3-6h M28-LUM (Day 15) (n=55)1660 ± 843
C3-6h M1-IVA (Day 15) (n=55)2670 ± 1330
C3-6h M6-IVA (Day 15) (n=55)4360 ± 2340
C3-6h LUM (Week 4) (n=54)22000 ± 8470
C3-6h IVA (Week 4) (n=54)779 ± 389
C3-6h M28-LUM (Week 4) (n=54)1730 ± 884
C3-6h M1-IVA (Week 4) (n=54)2800 ± 1410
C3-6h M6-IVA (Week 4) (n=54)4690 ± 3360
Ctrough LUM (Week 4) (n=53)12300 ± 6780
Ctrough IVA (Week 4) (n=53)171 ± 228
Ctrough M28-LUM (Week 4) (n=53)1780 ± 903
Ctrough M1-IVA (Week 4) (n=53)684 ± 816
Ctrough M6-IVA (Week 4) (n=53)2490 ± 2150
Ctrough LUM (Week 16) (n=53)11500 ± 6020
Ctrough IVA (Week 16) (n=52)153 ± 150
Ctrough M28-LUM (Week 16) (n=53)1610 ± 859
Ctrough M1-IVA (Week 16) (n=53)690 ± 627
Ctrough M6-IVA (Week 16) (n=53)2360 ± 1570
Ctrough LUM (Week 24) (n=51)11400 ± 5300
Ctrough IVA (Week 24) (n=51)118 ± 87.2
Ctrough M28-LUM (Week 24) (n=51)1710 ± 947
Ctrough M1-IVA (Week 24) (n=51)493 ± 409
Ctrough M6-IVA (Week 24) (n=51)1790 ± 1180

Adverse events

Collected over Part A: Day 1 up to Day 28; Part B: Day 1 up to Week 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Cohort 1: LUM/IVA—0/5 (0%)4/5 (80%)
Part A Cohort 2: LUM/IVA—0/5 (0%)3/5 (60%)
Part B: LUM/IVA—4/58 (6.9%)55/58 (94.8%)
Most frequent serious events
Most frequent serious events
EventPart A Cohort 1: LUM/IVAPart A Cohort 2: LUM/IVAPart B: LUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/50/52/58
IleusGastrointestinal disorders0/50/51/58
Alanine aminotransferase increasedInvestigations0/50/51/58
Aspartate aminotransferase increasedInvestigations0/50/51/58
Most frequent other events
Showing 10 of 118
Most frequent other events
EventPart A Cohort 1: LUM/IVAPart A Cohort 2: LUM/IVAPart B: LUM/IVA
CoughRespiratory, thoracic and mediastinal disorders1/53/529/58
HeadacheNervous system disorders2/51/512/58
Nasal CongestionRespiratory, thoracic and mediastinal disorders0/51/512/58
Abdominal pain upperGastrointestinal disorders1/50/58/58
ConstipationGastrointestinal disorders1/50/55/58
DiarrhoeaGastrointestinal disorders1/50/54/58
Forced Expiratory Volume DecreasedInvestigations0/51/50/58
Hepatic Enzyme IncreasedInvestigations1/50/50/58
LymphadenopathyBlood and lymphatic system disorders1/50/51/58
PyrexiaGeneral disorders1/50/56/58

Baseline characteristics

The Safety Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Lumacaftor/Ivacaftor (LUM/IVA)
Part A Cohort 1 (n=5)6.6 ± 0.89
Part A Cohort 2 (n=5)9.6 ± 0.89
Part B (n=58)9.1 ± 1.53
Sex/Gender, Customized
Sex/Gender, Customized(participants)Lumacaftor/Ivacaftor (LUM/IVA)
Part A Cohort 1 (n=5): Female1
Part A Cohort 1 (n=5): Male4
Part A Cohort 2 (n=5): Female1
Part A Cohort 2 (n=5): Male4
Part B (n=58): Female31
Part B (n=58): Male27
08

Study locations

20 sites
  • Birmingham, Alabama, United States
  • Tucson, Arizona, United States
  • Long Beach, California, United States
  • Palo Alto, California, United States
  • Aurora, Colorado, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Boston, Massachusetts, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Buffalo, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • Charleston, South Carolina, United States
  • Austin, Texas, United States
  • Salt Lake City, Utah, United States
  • Norfolk, Virginia, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Toronto, Ontario, Canada
09

References and documents

Publications

  • Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol. 1993 Feb;15(2):75-88. doi: 10.1002/ppul.1950150204. PubMed 8474788 ↗
  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group *. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2017 Apr 1;195(7):912-920. doi: 10.1164/rccm.201608-1754OC. PubMed 27805836 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2013
First posted
Jul 11, 2013
Start
Jul 2013
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results first posted
Dec 5, 2016
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01897233
Responsible party
Sponsor
First posted
Jul 11, 2013
Start date
Jul 2013
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Dec 5, 2016
Last update
Jun 20, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumacaftor

Start the discussion